Medicure Inc. Overview
Pro stress-test →Medicure Inc. is a cardiovascular drug discovery and development company focused on developing therapeutics for unmet needs in the field of cardiovascular medicine. The company markets AGGRASTAT injection for acute coronary syndrome and ZYPITAMAG for hyperlipidemia treatment. In 2025, Medicure acquired Gateway Medical Pharmacy and West Olympia Pharmacy, expanding its direct-to-consumer pharmacy operations.
Strategic Profile
Pro stress-test →In Q1 2026 (ended March 31, 2026), Medicure reported net revenue of CAD 7.9 million versus CAD 5.5 million in Q1 2025, reducing net loss to CAD 406,000 from CAD 694,000 year-over-year. The company aims to accelerate growth of ZYPITAMAG and other products through direct-to-consumer sales, which improve patient access, medication adherence, and reduce distribution costs. Pipeline candidates include MC-1 for PNPO deficiency and TARDOXAL for neurological indications such as Tardive Dyskinesia.
Competitive Landscape
Pro stress-test →AGGRASTAT faces competition from generic tirofiban hydrochloride; Medicure remains the only manufacturer of the 3.75 mg bolus vial format. ZYPITAMAG (pitavastatin) competes in a crowded statin market dominated by established generics and branded alternatives. Direct-to-consumer pharmacy operations compete with mail-order and telehealth pharmacy platforms. Pipeline candidates (MC-1, TARDOXAL) target smaller niche indications with less competition but smaller addressable markets.
Industry Context
Medicure Inc. operates in Specialty biopharmaceuticals and direct pharmacy distribution.
Key facts
Founded: 1997 · Headquarters: Winnipeg, Canada · Revenue: CAD 7.9M (Q1 2026 quarterly)